Position in NVS
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$2,287,798
+$73,076 QoQ
Shares Held
14,598
+0.7% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.53%
of 13F equity value
Holder Rank
#400
of 1,603 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Abel Hall, LLC holds $16,989,938 across 13 Drug Manufacturers - General names. NVS ranks #3 (13.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
2,675 | $3,208,475 | |
| 2 | JNJ |
Johnson & Johnson
|
9,158 | $2,325,857 | |
| 3 | NVS |
Novartis AG
This page
|
14,598 | $2,287,798 | |
| 4 | ABBV |
AbbVie Inc.
|
7,378 | $1,856,599 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
20,767 | $1,196,594 | |
| 6 | MRK |
Merck & Co., Inc.
|
7,789 | $1,000,886 | |
| 7 | PFE |
Pfizer Inc
|
40,621 | $978,153 | |
| 8 | NVO |
Novo Nordisk A S
|
19,198 | $920,352 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,287,798 | 14,598 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $2,214,722 | 14,499 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $1,711,793 | 12,416 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $627,478 | 4,893 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $506,184 | 4,183 | Shares | Sole | 2025-07-23 | |
| 2025-03-31 | $525,516 | 4,714 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $368,999 | 3,792 | Shares | Sole | 2025-01-23 | |
| 2024-09-30 | $426,724 | 3,710 | Shares | Sole | 2024-11-15 | |
| 2024-06-30 | $378,252 | 3,553 | Shares | Sole | 2024-07-25 | |
| 2024-03-31 | $309,729 | 3,202 | Shares | Sole | 2024-05-08 | |
| 2023-12-31 | $314,016 | 3,110 | Shares | Sole | 2024-02-28 | |
| No filing history on record for this holder in this stock. | ||||||